ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sekisui Gets Rival Diagnostics Firm

by Jean-François Tremblay
November 30, 2015 | APPEARED IN VOLUME 93, ISSUE 47

Sekisui Chemical will pay $183 million to the Japanese drug firm Eisai to buy its Eidia unit, a provider of clinical diagnostic reagents, clinical analyzers, and laboratory reagents used in the treatment of cancer and rheumatism. Sekisui already has a diagnostic business concentrated on diabetes, blood disorders, hyperlipidemia, and infectious diseases. After the acquisition, Sekisui intends to promote Eidia’s products internationally. Traditionally a producer of plastics and residential homes, Sekisui is seeking to boost its life sciences business.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment